You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

shingrix_logo

Product menu

SHINGRIX: Recommended by the Saudi Arabia MOH & CDC for the prevention of shingles1,8*†

Saudi Arabia National Immunization Program recommends HZ vaccine (SHINGRIX) 2-doses 2-6 months apart for adults aged ≥ 50 years old for HZ8

The CDC states that SHINGRIX is1:

shingrix_icons_checked

Recommended for the prevention of herpes zoster and related complications for immunocompetent adults aged ≥50 years

shingrix_icons_checked

Recommended for the prevention of herpes zoster and related complications for immunocompetent adults who previously received zoster vaccine live (ZVL)

shingrix_icons_checked

Preferred over ZVL for the prevention of herpes zoster and related complications

†Important Considerations for CDC Recommendations3,4

  • There are limited data on vaccination with SHINGRIX in patients previously vaccinated with ZVL
    • In a phase 3 study, humoral immunogenicity was noninferior among subjects previously vaccinated at least 5 years earlier with ZVL
    • No apparent safety differences were observed between study groups within 30 days post-dose 2 of SHINGRIX
    • Solicited local and systemic symptoms were similar between study groups
  • The levels of antibodies and immune cells that correlate with protection against shingles have not been clearly defined
  • There are no head-to-head clinical trials comparing the efficacy and safety of SHINGRIX to ZVL

ACIP=Advisory Committee on Immunization Practices; CDC=US Centers for Disease Control and Prevention; ZVL=zoster vaccine live.

*ACIP recommendations adopted by the CDC.

shingrix_icons_efficacy

See the SHINGRIX efficacy data4

SHINGRIX delivered >90% efficacy against shingles in all age segments ≥50 years old

Learn more

shingrix_icons_people

Meet the patients you can protect4-7

Nearly everyone ≥50 years old needs shingles protection

Learn more

shingrix_icons_double_injections

Make SHINGRIX a part of your practice

Discover more about administering the vaccine and discussing shingles and vaccination with your patients

Learn more

Shingrix Safety Information4

Contraindications:
Hypersensitivity to the active substances or to any component of the vaccine.

Special warnings and precautions:
As with all injectable vaccines:
- appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine;
- vaccination with Shingrix should be postponed in subjects suffering from an acute severe febrile illness. The presence of a minor infection, such as a cold, should not result in the deferral of vaccination;
- a protective immune response may not be elicited in all vaccinees.
Do not administer the vaccine intravascularly, intradermally or subcutaneously.
There are no data on the use of Shingrix in pregnant women and the effect on breast-fed infants of administration of Shingrix to their mothers has not been studied.

Adverse reactions:
- Very common (≥1/10): headache, gastrointestinal symptoms (including nausea, vomiting, diarrhoea and/or abdominal pain), myalgia, injection site reactions (such as pain, redness, swelling), fatigue, chills, fever.
- Common (≥1/100 to <1/10): injection site pruritus, malaise.
Please refer to the full prescribing information for further details.

References

  1. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR. 2018 Jan;67(3):103-8.
  2. Centers for Disease Control and Prevention. Shingles vaccination [updated January 2018; accessed May 2020]. Available from: https://www.cdc.gov/vaccines/vpd/shingles/public/shingrix/index.html.
  3. Grupping K, Campora L, Douha M, Heineman TC, Klein NP, Lal H, et al. Immunogenicity and safety of the HZ/su adjuvanted herpes zoster subunit vaccine in adults previously vaccinated with a live attenuated herpes zoster vaccine. J Infect Dis. 2017 Dec;216(11):1343-51.
  4. Shingrix local prescribing information based on GDS V07.
  5. Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-18.
  6. Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med. 2007 Mar;356(13):1338-43.
  7. Centers for Disease Control and Prevention. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008 May;57(RR-5):1-30.
  8. Saudi Arabia Ministry of Health, National Immunization Schedule, 2020, 1-2.

For more information, please refer to the prescribing information or contact GSK: P.O Box 55850, Jeddah, 21544, Kingdom of Saudi Arabia.
Telephone: +966 12 653 6666 or via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via saudi.safety@gsk.com
To report the Quality related product complaint/s associated with the use of GSK product/s, please contact us via ksa.productqualitycomplaint@gsk.com

GSK does not recommend, endorse or accept liability for sites controlled by a third party.

Trademarks are owned by or licensed to the GSK group of companies.
©2024 GSK group of companies or its licensor
GlaxoSmithKline, Jeddah, 21544, Kingdom of Saudi Arabia.

PM-SA-SGX-WCNT-220001 Date of preparation: September 2024